Abstract: MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.

Content Format:

PDF

Credit Type:

--

Credits:

--
MOUNTAINEER-03 (NCT05253651) is a global, open-label,  randomized, phase 3 study of tucatinib with trastuzumab and  mFOLFOX6 versus standard of care for the first-line treatment of  HER2+ and RAS wild-type mCRC

Content Format:

Slideset

Credit Type:

--

Credits:

--